SIGLEC9 and non-small cell lung carcinoma: Stanczak et al. discovered that SIGLEC9 was upregulated in the tumor-infiltrating T cells in the tumor microenvironment of colorectal cancer, ovarian cancer, and non-small cell lung cancer (14).